<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146181</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-I10A-B201</org_study_id>
    <nct_id>NCT04146181</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase II, Multicenter, Single-arm, Open-label Study of SCT-I10A in Patients With Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Who Progressed on or After Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of SCT-I10A for Recurrent/
      Metastatic Head and Neck Squamous cell Carcinoma who progressed on or after platinum-based
      chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single-arm and multicenter phase II study designed to evaluate
      Objective Response Rate (ORR) of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous
      cell Carcinoma who progressed on or after platinum-based chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SCT-I10A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1</intervention_name>
    <description>SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.</description>
    <arm_group_label>SCT-I10A</arm_group_label>
    <other_name>SCT-I10A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily participate in this clinical trial and sign an informed consent form;

          2. Male or female, age ≥ 18 years old;

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          4. Has histologically- or cytologically-confirmed recurrent or metastatic (disseminated)
             head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and
             larynx;

          5. Is considered incurable by local therapies;

          6. Have measurable disease based on RECIST1.1. tumor lesions, situated in a previously
             irradiated area are considered measurable if progression has been demonstrated in such
             lesion after 3 months of radiotherapy;

          7. Have provided tissue for PD-L1 biomarker analysis

          8. The estimated survival period is ≥ 3 months;

          9. Patients who have been treated with platinum (cisplatin/carboplatin/nidaplatin) and
             have clear disease progression during treatment (at least 2 cycles) or after treatment
             (see RECIST version 1.1) or side effects Intolerance, and the minimum dose of platinum
             drugs must meet:

             Minimum dose of cisplatin: ≥60mg/m2 per cycle, or ≥120mg/m2 in 8 weeks; The minimum
             dose of carboplatin: AUC ≥ 4 / cycle, or total AUC ≥ 8 within 8 weeks.

             If cisplatin is converted to platinum, the platinum dosage can be calculated using the
             following formula: carboplatin 1AUC = cisplatin 15mg/m2; The minimum dose of
             nedaplatin: ≥80mg/m2 per cycle, or ≥160mg/m2 in 8 weeks; Note: Platinum drugs can be
             used as adjuvant therapy for postoperative patients (synchronous radiotherapy), for
             palliative chemotherapy in patients with advanced stage or in patients with recurrent
             and/or metastatic disease.

         10. Laboratory inspection:

             Blood routine: neutrophils ≥1.5×l09/L, platelets≥75×109/L, hemoglobin≥80g/L; Liver
             function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ALT and
             AST ≤ upper limit of normal value × 3 for liver metastasis, ALT and AST ≤ upper limit
             of normal value for liver metastases × 5; total bilirubin ( TBIL) ≤ upper limit of
             normal value × 1.5; Renal function: creatinine (Cr) ≤ normal upper limit × 1.5;
             Coagulation: Activated Partial Thromboplastin Time (aPTT), International Normalized
             Ratio (INR), Prothrombin Time (PT) ≤1.5xULN Echocardiogram: LVEF≥50%

         11. Subjects should agree to use an adequate method of contraception starting with the
             first dose of study medication through 6 months after the last dose of study therapy.
             Female subjects of childbearing potential should have a negative blood pregnancy test
             within 7 days prior to receiving the first dose of study medication, and should be
             non-breastfeeding;

        Exclusion Criteria:

          1. Disease is suitable for local therapy administered with curative intent

          2. Prior therapy with an anti-PD-1 or anti-PD1-L1 or -L2 therapy, or anti-CD137, or
             anti-CTLA-4 therapy

          3. Diagnosed and/or treated additional malignancy within 5 years of randomization, with
             the exception of curatively-treated basal cell or squamous cell carcinoma of the skin,
             and/or curatively-resected in situ cervical cancers;

          4. NCI CTCAE v5.0 Grading of Peripheral Neuropathy≥2;

          5. Active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             subjects with previous treated brain metastases may participate provided they are
             stable for at least 2 weeks prior to the first dose of study medication, have no
             evidence of new or enlarging brain metastases, and are not using steroids for at least
             14 days prior to trial treatment. Subjects with asymptomatic BM (without neurological
             symptoms, not using steroids, tumor lesions≤1.5cm) may participate in condition that
             the tumor lesion should be regularly evaluated using identical imaging modality for
             each assessment, either MRI or CT scans;

          6. At the time of enrollment, patients still had ≥2 toxic side effects (except for hair
             loss, hearing loss, tinnitus, dry mouth or platinum-induced grade 2 neurotoxicity)
             caused by previous anti-tumor treatment;

          7. Has known serious allergic reaction to study medication or any component of the
             product, and has known serious allergic reaction to other monoclonal antibodies (NCI
             CTCAE v5.0≥3);

          8. Has received anti-tumor therapy, including chemotherapy, hormonal therapy,
             immunotherapy, radiotherapy, and etc. within 4 weeks of the first dose of treatment,
             except palliative radiotherapy for bone pain;

          9. Has received any Chinese traditional medicine for anti-cancer purpose within 1 week of
             the first dose of treatment;

         10. Has undergone important surgery within 4 weeks prior to first dose of treatment or has
             scheduled an important surgery during the study;

         11. Has received immunosuppressive drugs during the study or within 2 weeks prior to first
             dose of treatment, except for the following situations:

             Intranasal, inhaled, topical corticosteroids (e.g. intra-articular injections);
             Physiological dose for systemic prednisolone (≤10mg/d or equivalent); Short-term
             administration (≤7days) of corticosteroids for prophylaxis or treatment against
             non-autoimmune allergic disease

         12. Has known active, and/ or history of autoimmune disease (systemic lupus erythematous,
             rheumatoid arthritis, inflammatory bowel disease, AITD, multiple sclerosis,
             vasculitis, glomerulonephritis), and is likely to get a recurrence, or is at high-risk
             (organ-transplanted patients need immunotherapy), except those with stable type 1 DM
             after fixed dose of insulin administration , or those with autoimmune hypothyroidism
             only require HRT, or those with skin disorders that does not require systemic
             treatment (e.g. eczema, rash &lt;10% BSA, psoriasis without symptoms around eyes)

         13. Has known interstitial lung disease, such as interstitial pneumonia, pulmonary
             fibrosis, except asymptomatic drug-induced pneumonitis or radiation pneumonitis

         14. Has a known history of HIV

         15. Has known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C(e.g. HCV RNA
             [quantitative] is detected)

         16. has uncontrolled active infections within 2 weeks before enrollment

         17. Has received a live vaccine within 4 weeks prior to first dose of study treatment,
             except

         18. Is with clinical symptoms, required clinical intervention or stable time less than 4
             weeks of serous cavity effusion (such as pleural effusion and ascites);

         19. Has severe conditions, including NYHA III heart failure, IHD, history of MI within 3
             months prior to first dose of study treatment, poorly controlled DM (FBS≥10mmol/L) or
             poorly controlled hypertension (SBP≥160mmHg and/ or DBP≥100mmHg)

         20. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

         21. Is currently participating in other clinical trials, or has participated in a study of
             an investigational agent and received study therapy, or used an investigational
             device, any of whose end date is within 4 weeks prior to the first dose of study
             medication

         22. has alcohol or drug addiction;

         23. Subjects who are considered unsuitable for participating in this study for various
             reasons at the discretion of the investigator，such as inability to comply with study
             and/or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Wang, MD</last_name>
    <phone>15201286305</phone>
    <email>SCT-CT@sinocelltech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuankai Shi, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumour Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Qu, PhD</last_name>
      <email>13607887386@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

